IRAK-4-shRNA Prevents Ischemia/Reperfusion Injury Via Different Perfusion Periods Through the Portal Vein After Liver Transplantation in Rat-Reference-Cited by-同舟云学术

IRAK-4-shRNA Prevents Ischemia/Reperfusion Injury Via Different Perfusion Periods Through the Portal Vein After Liver Transplantation in Rat

Published:2016-10 Issue:8 Volume:48 Page:2803-2808
ISSN:0041-1345
Container-title:Transplantation Proceedings
language:en
Short-container-title:Transplantation Proceedings

Author:

Wu Y.,Liu Y.,Li M.,Liu Z.,Gong J.

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Transplantation,Surgery

Reference21 articles.

1. Current indications and contraindications for liver transplantation;Ahmed;Clin Liver Dis,2007

2. Analysis of ischemia/reperfusion injury in time-zero biopsies predicts liver allograft outcomes;Ali;Liver Transpl,2015

3. Liver ischemia/reperfusion injury: processes in inflammatory networks—a review;Abu-Amara;Liver Transpl,2010

4. The current state of knowledge of hepatic ischemia-reperfusion injury based on its study in experimental models;Mendes-Braz;J Biomed Biotechnol,2012

5. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity;Kim;J Exp Med,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-1 receptor-associated kinase family proteins: An overview of their role in liver disease;European Journal of Pharmacology;2024-09

2. Reperfusão Retrógrada no Transplante de Fígado: Uma Revisão Integrativa da Literatura;Brazilian Journal of Transplantation;2023-04-28

3. Retrograde Reperfusion in Liver Transplantation: An Integrative Literature Review;Brazilian Journal of Transplantation;2023-04-28

4. Normothermic Machine Perfusion (NMP) of the Liver as a Platform for Therapeutic Interventions during Ex-Vivo Liver Preservation: A Review;Journal of Clinical Medicine;2020-04-07

5. Therapeutics administered during ex vivo liver machine perfusion: An overview;World Journal of Transplantation;2020-01-18